Keywords
SARS CoV-2
Monoblastic Leukemia
Chemotherapy
Categories
How to Cite
Abstract
Introduction: Acute Leukemia (AL) is a heterogeneous neoplasm characterized by the monoclonal proliferation of immature cells. It is common in adults and its incidence increases with age. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV2) is a viral disease that manifests itself with respiratory symptoms. The severity and complications are greater in patients with risk factors or other comorbidities such as hypertension, diabetes, cancer, cerebrovascular disease, chronic obstructive pulmonary disease, or chronic kidney disease. Some studies even showed that the impact of the disease and the risk of complications among patients with cancer or other hematological malignancies increases. Case Report: Next, we present a case of COVID-19 pneumonia in a 65-year-old man with newly diagnosed Acute Leukemia and Acute Respiratory Distress Syndrome (ARDS). Conclusion: Oncology investigator groups and other expert reviews recommend screening for SARS-CoV-2 in all patients with acute leukemia before starting therapy, regardless of symptoms.
References
Pelcovits A, Niroula R. Acute Myeloid Leukemia: A Review. R I Med J 2020;103(3):38-40. PMID: 32236160.
Ruiz-Argüelles GJ, Garces-Eisele J, Reyes-Nunez V, Gomez-Rangel JD, Ruiz-Delgado GJ: More on geographic haematology: the breakpoint cluster regions of the PML/RAR alpha fusion gene in Mexican mestizo patients with promyelocytic leukaemia are different from those in Caucasians. Leuk Lymphoma 2004; 45: 1365–1368.
Gomez-Almaguer D, Marcos-Ramirez ER, Montano-Figueroa EH, Ruiz-Argüelles GJ, Best-Aguilera CR, Lopez-Sanchez MD, et al: Acute leukaemia characteristics are different around the world: the Mexican perspective. Clin Lymphoma Myeloma Leuk 2017; 17: 46–51.
Forman D, Stockton D, Moller H, Quinn M, Babb P, De Angelis R, et al: Cancer prevalence in the UK: results from the EUROPREVAL study. Ann Oncol 2003; 14: 648–654.
Jaime-Perez JC, Brito-Ramirez AS, Pinzon-Uresti MA, Gutierrez-Aguirre H, Cantu-Rodriguez OG, Herrera-Garza JL, et al: Characteristics and clinical evolution of patients with acute myeloblastic leukaemia in northeast Mexico: an eight-year experience at a university hospital. Acta Haematol 2014; 132: 144–151.
Colunga-Pedraza PR, Gómez-Cruz GB, Colunga-Pedraza JE, Ruiz-Argüelles GJ. Geographic haematology: some observations in México. Acta Haematol. 2018;140(2):114–20.
Cevik M, Bamford G, Ho A. COVID-19 pandemic–a focused review for clinicians. Clin Microbiol Infect 2020;26:842–847.
Kahathuduwa C, Dhanasekara C, Chin S.-H. Case fatality rate in COVID-19: a systematic review and meta-analysis. MedRxiv 2020.
Abate S.M, Ahmed Ali S, Mantfardo B, Basu B. Rate of intensive care unit admission and outcomes among patients with coronavirus: a systematic review and meta-analysis. PLoS One 2020;15:e0235653.
Pascarella G, Strumia A, Piliego C. COVID-19 diagnosis and management: a comprehensive review. J Intern Med 2020;288:192–206.
Saini K.S, Tagliamento M, Lambertini M. Mortality in patients with cancer and coronavirus disease 2019: a systematic review and pooled analysis of 52 studies. Eur J Cancer 2020;139:43–50.
Curigliano G, Banerjee S, Cervantes A. Panel Members Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus. Ann Oncol 2020;31:1320–1335.
Paul S, Rausch C.R, Jain N. Treating leukemia in the time of COVID-19. Acta Haematologica 2020:1–13.
AML working party COVID-19 recommendations [Jun;2020];http://www.cureleukaemia.co.uk/page/news/523/aml-working-party-covid-19 recommendations. 2020
Percival MEM, Lynch RC, Halpern AB, et al. Considerations for managing patients with hematologic malignancy during the COVID-19 pandemic: the Seattle strategy. J Oncol Pract 2020
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2022 Revista de Medicina Clínica